Format

Send to

Choose Destination
Clin Sci (Lond). 2015 Dec;129(12):989-99. doi: 10.1042/CS20150436.

Nrf2 in health and disease: current and future clinical implications.

Author information

1
Department of Anatomy and Cell Biology, University Hospital, RWTH Aachen University, Aachen, Germany othman.al-sawaf@rwth-aachen.de cwruck@ukaachen.de.
2
Institute of Neuroanatomy, University Hospital, RWTH Aachen University, Aachen, Germany.
3
Department of Orthopaedic Surgery, University Hospital, RWTH Aachen. Germany.
4
Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94115, U.S.A.
5
Department of Anatomy and Cell Biology, University Hospital, RWTH Aachen University, Aachen, Germany.
6
Department of Internal Medicine III - Gastroenterology and Metabolic Disorders, University Hospital RWTH Aachen, Aachen, Germany.

Abstract

The transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) is a major regulator of oxidative stress defence in the human body. As Nrf2 regulates the expression of a large battery of cytoprotective genes, it plays a crucial role in the prevention of degenerative disease in multiple organs. Thus it has been the focus of research as a pharmacological target that could be used for prevention and treatment of chronic diseases such as multiple sclerosis, chronic kidney disease or cardiovascular diseases. The present review summarizes promising findings from basic research and shows which Nrf2-targeting therapies are currently being investigated in clinical trials and which agents have already entered clinical practice.

KEYWORDS:

Nrf2; cardiovascular disease; chronic kidney disease; clinical trials; multiple sclerosis; oxidative stress

PMID:
26386022
DOI:
10.1042/CS20150436
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center